AR123474A1 - Vesículas de la membrana externa - Google Patents
Vesículas de la membrana externaInfo
- Publication number
- AR123474A1 AR123474A1 ARP210102509A ARP210102509A AR123474A1 AR 123474 A1 AR123474 A1 AR 123474A1 AR P210102509 A ARP210102509 A AR P210102509A AR P210102509 A ARP210102509 A AR P210102509A AR 123474 A1 AR123474 A1 AR 123474A1
- Authority
- AR
- Argentina
- Prior art keywords
- gonococcal
- bacterium
- polypeptide
- expression
- function
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title abstract 3
- 241000894006 Bacteria Species 0.000 abstract 10
- 108020004999 messenger RNA Proteins 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 230000003247 decreasing effect Effects 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 101150031313 rmp gene Proteins 0.000 abstract 2
- 102000057234 Acyl transferases Human genes 0.000 abstract 1
- 108700016155 Acyl transferases Proteins 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000012239 gene modification Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/36—Neisseria
Abstract
La presente invención se refiere al campo de las composiciones de vacunas de neisseria (en particular las composiciones de vacunas gonocócicas) y al uso detales composiciones en medicina. Más en particular, la presente invención se refiere a gonococos genéticamente modificados de la cepa FA1090 y vesículas de la membrana externa obtenidas a partir de los mismos. La invención también proporciona un proceso para la preparación de los gonococos genéticamente modificados de la invención, así como también composiciones inmunogénicas y vacunas que comprenden las vesículas de la membrana externa de la invención. Reivindicación 1: Una bacteria gonocócica genéticamente modificada de la cepa FA1090, que comprende modificaciones genéticas que: a. disminuyen o anulan la expresión y/o función del gen, ARNm y/o polipéptido de lauroil aciltransferasa (lpxl1) de biosíntesis del lípido A; y b. disminuyen o anulan la expresión y/o función del gen, ARNm y/o polipéptido de la proteína modificable por reducción (rmp). Reivindicación 6: Un proceso para la producción de la bacteria gonocócica de acuerdo con las reivindicaciones 1 a 5, el proceso comprende: a) la disminución o anulación de la expresión y/o función del ARNm y/o el polipéptido del gen lpxl1 en una bacteria gonocócica FA1090 para producir una primera bacteria gonocócica FA1090 y la disminución o anulación de la expresión y/o función del ARNm y/o el polipéptido del gen rmp de la primera bacteria gonocócica FA1090 para producir una segunda bacteria gonocócica FA1090; o b) la disminución o anulación de la expresión y/o función del ARNm y/o el polipéptido del gen rmp de la primera bacteria gonocócica FA1090 para producir una primera bacteria gonocócica FA1090 y la disminución o anulación de la expresión y/o función del ARNm y/o el polipéptido del gen lpxl1 de la primera bacteria gonocócica FA1090 para producir una segunda bacteria gonocócica FA1090.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20195709 | 2020-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123474A1 true AR123474A1 (es) | 2022-12-07 |
Family
ID=72473456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102509A AR123474A1 (es) | 2020-09-11 | 2021-09-09 | Vesículas de la membrana externa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230321213A1 (es) |
| EP (1) | EP4211147A1 (es) |
| JP (1) | JP2023541876A (es) |
| KR (1) | KR20230066041A (es) |
| CN (1) | CN116096871A (es) |
| AR (1) | AR123474A1 (es) |
| AU (1) | AU2021339930A1 (es) |
| BR (1) | BR112023003571A2 (es) |
| CA (1) | CA3194346A1 (es) |
| IL (1) | IL300922A (es) |
| MX (1) | MX2023002786A (es) |
| WO (1) | WO2022053535A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| AU2011300418B2 (en) | 2010-09-10 | 2016-05-12 | Glaxosmithkline Biologicals Sa | Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom |
-
2021
- 2021-09-09 EP EP21773104.1A patent/EP4211147A1/en active Pending
- 2021-09-09 KR KR1020237011635A patent/KR20230066041A/ko unknown
- 2021-09-09 IL IL300922A patent/IL300922A/en unknown
- 2021-09-09 BR BR112023003571A patent/BR112023003571A2/pt unknown
- 2021-09-09 AR ARP210102509A patent/AR123474A1/es unknown
- 2021-09-09 CA CA3194346A patent/CA3194346A1/en active Pending
- 2021-09-09 WO PCT/EP2021/074744 patent/WO2022053535A1/en active Application Filing
- 2021-09-09 CN CN202180062246.XA patent/CN116096871A/zh active Pending
- 2021-09-09 MX MX2023002786A patent/MX2023002786A/es unknown
- 2021-09-09 AU AU2021339930A patent/AU2021339930A1/en active Pending
- 2021-09-09 JP JP2023515724A patent/JP2023541876A/ja active Pending
- 2021-09-09 US US18/025,273 patent/US20230321213A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4211147A1 (en) | 2023-07-19 |
| WO2022053535A1 (en) | 2022-03-17 |
| KR20230066041A (ko) | 2023-05-12 |
| JP2023541876A (ja) | 2023-10-04 |
| BR112023003571A2 (pt) | 2023-04-04 |
| AU2021339930A1 (en) | 2023-04-20 |
| US20230321213A1 (en) | 2023-10-12 |
| CA3194346A1 (en) | 2022-03-17 |
| IL300922A (en) | 2023-04-01 |
| CN116096871A (zh) | 2023-05-09 |
| MX2023002786A (es) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2121013T3 (en) | Methods for preparing yeast-based vaccines | |
| BR112012022688A2 (pt) | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão | |
| Bachmann et al. | Dendritic cells process exogenous viral proteins and virus‐like particles for class I presentation to CD8+ cytotoxic T lymphocytes | |
| BR112012022800A2 (pt) | composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica | |
| ECSP10010723A (es) | Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso | |
| AR061333A1 (es) | Composiciones de vacuna de la neisseria | |
| AR118389A1 (es) | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización | |
| ECSP22052002A (es) | Métodos de cultivo de células, preparación de hidrolizado a partir de células y aplicaciones de los mismos | |
| EP4226938A2 (en) | Coronavirus vaccine | |
| Hui et al. | Antigen-encapsulating host extracellular vesicles derived from Salmonella-infected cells stimulate pathogen-specific Th1-type responses in vivo | |
| Baker et al. | Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine | |
| BRPI0411519A (pt) | membrana viral reconstituìda, método para produzir uma membrana viral reconstituìda, e, composição farmacêutica | |
| BR112015012711A2 (pt) | método de produção de uma vacina de mycoplasma | |
| US20200085933A1 (en) | Bordetella vaccines comprising LPS with reduced reactogenicity | |
| Beijnen et al. | Vaccine-induced CD8+ T cell responses in children: a review of age-specific molecular determinants contributing to antigen cross-presentation | |
| WO2023147092A2 (en) | Coronavirus vaccine | |
| AR123474A1 (es) | Vesículas de la membrana externa | |
| CL2023001142A1 (es) | Composiciones y métodos para la vacunación contra neisseria gonorrhoeae | |
| Kaur et al. | Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge | |
| Kogo et al. | Suppression of murine tumour growth through CD 8+ cytotoxic T lymphocytes via activated DEC‐205+ dendritic cells by sequential administration of α‐galactosylceramide in vivo | |
| WO2022120388A3 (en) | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof | |
| CO2023010612A2 (es) | Vacuna recombinante meningocócica b | |
| BR112015013625A2 (pt) | adjuvante de vacinação, preparação e vacinas contendo o mesmo | |
| BR0316687A (pt) | Composição e adjuvante vacinal e método para a obtenção de estruturas cocleares a partir de vesìculas de membrana externa de organismos vivos | |
| BR112013010338A2 (pt) | composição, métodos para preparar uma composição imunogênica, para adjuvantar uma resposta imune, para eliciar uma resposta imune contra um agente infeccioso, para evitar e/ou reduzir a deposição de amilóide ou doença de alzheimer em um indivíduo, e para tratar/reduzir/melhorar a infecção por uma agente infeccioso, uso de uma proteína, e, kit |